IL-32 has been mooted as a biomarker in skin conditions including atopic dermatitis and melanoma (84) and ascribed a proinflammatory, host-protective role in tuberculosis, leishmaniasis, colitis, and arthritis on the basis of the use of human IL32–transgenic (huIL32-transgenic) mouse models. This evidence concerns the gene IL32 and arthritic joint disease.